Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase 2b study of DUR-928 in severe alcohol-associated hepatitis
2020-004534-38Phase 2Completed
- Sponsor
- DURECT Corporation
- Start
- Jun 2021
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 2, randomised, double-blind trial of larsucosterol in alcoholic hepatitis (AH) (3 arms), sponsored by DURECT Corporation. Primary endpoint: 90-day mortality or transplant. Started Jun 2021; status: completed.
02
Drugs
larsucosterol
03
Conditions
alcoholic hepatitis (AH)
Beyond the preview
Go deeper on 2020-004534-38.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2020-004534-38.